EQUITY ALERT: The Rosen Law Firm Announces Investigation of Idenix Pharmaceuticals Inc. (IDIX) Concerning the Proposed Acquisition by Merck & Co., Inc. (MRK)

NEW YORK--(BUSINESS WIRE)--

The Rosen Law Firm, P.A. is investigating the Board of Directors of Idenix Pharmaceuticals Inc. IDIX for possible breaches of fiduciary duties and other violations of law by failing to adequately shop Idenix to maximize shareholder value before entering into an agreement with Merck & Co., Inc. MRK.

If you would like to join the action, please call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free, at 866-767-3653; or email at pkim@rosenlegal.com or kchan@rosenlegal.com. There is no cost or obligation to you.

Under the terms of the proposed transaction, shareholders will receive $24.50 in cash for each share of Idenix stock they own. The proposed transaction is valued at approximately $3.85 billion. The investigation relates to whether the proposal is fair to public shareholders and whether Idenix's Board of Directors breached its fiduciary duties in connection with the proposed transaction.

If you own and purchased Idenix common stock before June 9, 2014 and wish to obtain additional information, please visit the website at http://rosenlegal.com/buyoutcases.html. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.